[Treatment of coronary disease with elantan. Results of a multicenter study].
10,229 patients with coronary heart disease (CHD) took part in a multicenter study to verify the efficacy and tolerance of a 14 days lasting therapy with elantan under practical conditions. The majority of patients with an average age of 59 +/- 10 years (58.8% men, 40.3% women) had suffered about four years on CHD and had already been treated with coronary efficient drugs. The 14-day therapy with elantan 20 in a dosage of 3 X 1 tabl./day showed a cure rate of 79.9% in patients who had already been treated, a complete remission of the angina pectoris attacks being achieved in 50% and a reduction of the frequency of the attacks in a further 29.9%. The reduced frequency of the attacks was associated with a reduced consumption of acute nitrates (nitroglycerine capsules). With the smaller group of patients who were being treated for angina pectoris for the first time, the therapy with elantan was characterized by a cure rate of 91%.
D000787:Angina Pectoris / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate
Behandlung der koronaren Herzkrankheit mit elantan. Ergebnisse einer Multicenter-Studie.